Arrowhead Pharmaceuticals, Inc. has 13 Schedule 13D or 13G filings on record since 2025-07-29. 4 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 10.1% | 14,232,545 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| Avoro Capital Advisors LLC | 9.64% | 13,823,383 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Fmr LLC | 5.2% | 7,349,107 | SCHEDULE 13G, 2026-05-06 | 2026-03-31 |
| Vanguard Capital Management | 5.05% | 7,081,293 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| State Street Corporation | 4.6% | 6,371,056 | SCHEDULE 13G, 2025-08-11 | 2025-06-30 |
| Vanguard Portfolio Management | 4.53% | 6,384,903 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Sarepta Therapeutics, Inc. | 0% | 0 | SCHEDULE 13D/A, 2025-08-15 | 2025-08-13 |
Purpose of Transaction (Item 4)
Sarepta Therapeutics, Inc.
Item 4 of the Original Schedule 13D is hereby amended by adding the following: On August 13, 2025, Sarepta Investments sold 9,265,312 shares of the Issuer's Common Stock at a price of $18.79 per share in a privately negotiated block trade pursuant to Rule 144 of the Securities Act of 1933, as amended (the "Secondary Sale"). Also on August 13, 2025, concurrently with the Secondary Sale, Sarepta, Sarepta Investments and the Issuer entered into a Letter Agreement (the "Letter Agreement") pursuant to which the Issuer agreed to redeem and acquire from Sarepta Investments 2,660,989 shares of the Issuer's Common Stock (the "Redemption") in satisfaction of the obligation of Sarepta to pay the Issuer $49,999,983.31 of the DM1 First Development Milestone Payment (as such term is defined in Section 8.3.1(a)(i) of the Collaboration Agreement). The foregoing description of the Letter Agreement is not complete and is subject to and qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 99.5 hereto and incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2025-08-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 11.24% | SCHEDULE 13G/A |
| 2025-08-11 | State Street Corporation | 4.6% | SCHEDULE 13G |
| 2025-08-14 | Avoro Capital Advisors LLC | 8.3% | SCHEDULE 13G/A |
| 2025-08-15 | Sarepta Therapeutics, Inc. | 0% | SCHEDULE 13D/A |
| 2026-01-21 | BlackRock, Inc. | 15% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-24 | BlackRock, Inc. | 12.2% | SCHEDULE 13G/A |
| 2026-04-28 | Vanguard Portfolio Management | 5.19% | SCHEDULE 13G |
| 2026-04-29 | Vanguard Capital Management | 5.05% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 5.2% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 10.1% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Portfolio Management | 4.53% | SCHEDULE 13G/A |
| 2026-08-14 | Avoro Capital Advisors LLC | 9.64% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Arrowhead Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.